It is important to understand how mTOR inhibitors (including everolimus) function as effective adjunct therapies in diverse clinical settings, as rapamycin analogs, including everolimus, are currently being investigated as HDTs against TB in phase II clinical trials (Kim et al., 2004). This evidence concerns the gene MTOR and tuberculosis.